Br J Urol 1998 Dec;82(6):847-54
Service d'Urologie, Hôpital Henri Mondor, Creteil, France.
Br J Urol 1998 Jun;81(6):889-94
Department of Surgery, Hammersmith Hospital, London, UK.
Objective: To examine the safety and efficacy of transurethral pharmacotherapy for erectile dysfunction, involving the use of a novel therapeutic system to administer alprostadil (prostaglandin E1) to the urethral mucosa in a double-blind, randomized, parallel, placebo-controlled study conducted in five countries in Europe.
Patients And Methods: In an outpatient setting, patients with primarily organic erectile dysfunction of at least 3 months' duration were treated with transurethral alprostadil, in an open-label, dose-escalating study. Testing stopped when the dose provided an erection sufficient for intercourse, as assessed by the patient and the investigator. Read More
Urology 1998 May;51(5):687-92
Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA.
Objectives: Patients experiencing erectile dysfunction who fail intracavernous injection (ICI) therapy are commonly believed to have exhausted pharmacologic options. We evaluated the efficacy and safety of transurethral alprostadil (MUSE) in patients experiencing erectile dysfunction who underwent prior ICI therapy (alprostadil, papaverine, phentolamine, or a combination of these).
Methods: Of the 1511 patients enrolled in a multicenter trial of transurethral alprostadil, 452 (30%) reported prior ICI therapy and its effects. Read More
Int J Impot Res 2000 Apr;12(2):97-101
Department of Urology, Chung-Ang University Yongsan Hospital, Seoul, Korea.
A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. Read More
N Engl J Med 1997 Jan;336(1):1-7
Department of Urology, University of Southern California, Los Angeles, USA.
Background: Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat this disorder.
Methods: Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. Read More